<DOC>
	<DOCNO>NCT00079976</DOCNO>
	<brief_summary>To evaluate safety efficacy tigecycline treatment select serious infection cause VRE . The primary efficacy endpoint clinical response subject .</brief_summary>
	<brief_title>Study Evaluating Tigecycline Selected Serious Infections Caused Vancomycin-Resistant Enterococcus ( VRE ) Methicillin-Resistant Staphylococcus Aureus ( MRSA )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Gram-Positive Bacterial Infections</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<mesh_term>Tigecycline</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Male female subject age 18 year old Isolation one follow multiantibiotic resistant bacteria : vancomycinresistant Enterococcus faecium , vancomycinresistant Enterococcus faecalis , methicillinresistant Staphylococcus aureus , alone part polymicrobial infection Have confirm diagnosis serious infection ( eg , bacteremia [ unless due exclude infection ] , complicate intraabdominal infection , complicate skin skin structure infection , pneumonia ) require administration intravenous ( IV ) antibiotic therapy Subjects concomitant condition take concomitant medication , opinion investigator , could preclude evaluation response make unlikely contemplated course therapy followup assessment complete substantially increase risk associate subject 's participation study Anticipated length antibiotic therapy le 7 day For subject VRE , know suspected hypersensitivity tigecycline linezolid , compound related class antibacterial agent ( eg , oxazolidinones , tetracycline , minocycline , doxycycline ) . For subject MRSA , know suspected hypersensitivity tigecycline vancomycin , compound related class antibacterial agent ( eg , tetracycline , minocycline , doxycycline )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Staphylococcus aureus</keyword>
	<keyword>Bacterial Infections</keyword>
</DOC>